Tuesday, June 29, 2010

GORE PROPATEN® Vascular Graft


GORE PROPATEN® Vascular Graft



Addressing the problem of thrombus formation on the luminal surface of a vascular graft is a challenge faced by all vascular surgeons.

The GORE PROPATEN® Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.
Anything better below-knee would be a vein
Overall weighted average* primary patency based on GORE PROPATEN® Vascular Graft literature in below knee bypasses

*See references (PDF)

The GORE PROPATEN® Vascular Graft harnesses the anticoagulant properties of heparin directly at the luminal surface of the graft. The proprietary end-point attachment mechanism serves to anchor heparin molecules to the luminal surface while still maintaining heparin’s intrinsic bioactive properties. The result: a thromboresistant BioActive graft surface that retains its bioactive properties over time.

The GORE PROPATEN® Vascular Graft has demonstrated improved thromboresistance and patency compared to standard ePTFE grafts in pre-clinical in vivo tests. The thromboresistant surface technology employed on the GORE PROPATEN® Vascular Graft is designed to maintain bioactivity over an extended time period, thus increasing the potential for sustained performance improvement and increased patency*.

*Long-term data are not available regarding improved patency compared to marketed grafts.

No comments:

Post a Comment